InflaRx (NASDAQ:IFRX) Rating Increased to Strong-Buy at Zacks Research

Posted by George Bondi on Jul 29th, 2026

Zacks Research upgraded shares of InflaRx (NASDAQ:IFRX – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

Several other brokerages have also issued reports on IFRX. Cantor Fitzgerald increased their price target on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Oppenheimer initiated coverage on InflaRx in a research note on Friday, April 24th. They set an “outperform” rating and a $5.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, InflaRx presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Get Our Latest Research Report on InflaRx

InflaRx Trading Down 0.6%

IFRX stock opened at $1.69 on Monday. InflaRx has a 1-year low of $0.74 and a 1-year high of $2.95. The stock has a 50-day moving average price of $2.02 and a 200-day moving average price of $1.49. The firm has a market cap of $122.17 million, a PE ratio of -2.38 and a beta of 2.44.

InflaRx (NASDAQ:IFRX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, analysts forecast that InflaRx will post -0.29 earnings per share for the current year.

Institutional Investors Weigh In On InflaRx

Hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC lifted its stake in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the last quarter. HRT Financial LP purchased a new stake in InflaRx in the fourth quarter worth $47,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after buying an additional 19,200 shares during the last quarter. Insigneo Advisory Services LLC bought a new stake in shares of InflaRx in the fourth quarter valued at $61,000. Finally, Quadrature Capital Ltd purchased a new position in shares of InflaRx during the 4th quarter valued at $104,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.